How has ISB served as a catalyst for emerging biotechnology companies?
Over the last two years several new companies have emerged through the work of ISB. These include: Cytopeia, which produces high-speed cell sorters that use cell analysis techniques developed by ISB; MacroGenics, which uses genomics, proteomics and immunology to develop improved antibody therapies; and Celtrans, a start-up biotechnology company developing a therapeutic approach using blood stem cells in combination with traditional therapies to treat disease.
